Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
Cardiovascular-focused drug company reports financial results for Q2 2005
February 20th, 2005
Medicure Inc. (MCU), a cardiovascular drug discovery and development company, reported the results of operations for the 3 and 6 month periods ended November 30, 2004 As at November 30, 2004, the company had cash and cash equivalents totaling CDN$14,307,000 (US$11,514,688) compared to CDN$19,954,000 (US$16,059,557) as of May 31, 2004. The cash position is sufficient to fund completion of both the phase 2 portion of the MEND-CABG study and the MATCHED study and to advance lead products, MC-1 and MC-4232 up to pivotal phase 3 studies. Research and development expenditures during the quarter were CDN$3,068,000 (US$2,469,215) as compared to CDN$934,000...
Source: Medical Letter on the CDC & FDA (2005-02-20)
|
